Quanterix Corp

Quanterix lowered its full-year 2026 revenue guidance to a range of $142 million to $148 million from the prior $169 million to $174 million after second-quarter revenue of $32.9 million came in about $3 million, or 9%, below its May forecast. The company now anticipates achieving cash flow break-even in 2027 rather than year-end 2026 and expects to end 2026 with roughly $80 million in cash, down from about $100 million previously. Quanterix also announced commercial leadership changes, including the appointment of Jim Gute as chief commercial officer, and said it is reorganizing its sales force around solution-based selling. The company reported non-GAAP gross margin of 47.9% for the second quarter and adjusted EBITDA loss of $10.0 million.

Quanterix lowered its 2026 revenue guidance to $142 million to $148 million from $169 million to $174 million after second-quarter revenue of $32.9 million fell $3 million short of its own guidance amid broad market weakness and commercial execution challenges. The company also pushed its cash-flow breakeven target to 2027 and now expects to end 2026 with about $80 million in cash, down from a prior estimate of $100 million. On a pro forma basis including Akoya's pre-acquisition revenue, revenue declined 23% year over year, with Simoa revenue falling in the low teens and Spatial revenue declining as academic and government demand remained particularly weak. Quanterix completed its Akoya integration and achieved $85 million in annualized savings, helping lift non-GAAP gross margin to 47.9%. The company is restructuring its sales organization around product solutions and expects Simoa to recover more quickly than Spatial, while advancing its Alzheimer's diagnostics strategy with LucentAD Complete gaining coverage for qualifying Anthem members and targeting FDA approval for a blood-based biomarker test by late 2026.